Poster Sessions

PS-01-001: Investigating Homologous Recombination Deficiency in mCRPC through ctDNA
Georgios Vlachos, Austria
Abstract

PS-01-002: Identification of Therapeutically Relevant Mutations in Circulating Tumor DNA at Baseline to Assist in Treatment Decision Making
Paul van der Leest, The Netherlands
Abstract

PS-01-003: Epigenetic Biomarker Identification in Prostate Cancer using Liquid Biopsy Approaches
Rakesh Trivedi, United States
Abstract

PS-01-005: Detection of minimal residual disease in acute myeloid leukemia using microfluidics
Alexandra Teixeira, Portugal
Abstract

PS-01-006: Optimization of the characterization of plasma cell-free DNA integrity using a droplet-based digital PCR multiplex assay: towards the development of circulating tumor DNA multiplex assay
Valerie Taly, France
Abstract

PS-01-007: ddPCR, qPCR, and NGS performance to detect KRAS and EGFR mutations in plasma cell-free DNA of stage IIIB/IV lung adenocarcinoma patients, and comparison with the tissue molecular profile
Ernst Jan Speel, The Netherlands
Abstract

PS-01-008: Cross-Platform Biomarker Program for Establishment and Validation of Liquid Biopsy for Clinical Decision Making in resectable Gastrointestinal Stromal Tumour (GIST)
Helen Sievert, Germany
Abstract

PS-01-009: Identifying the Levers of Cost-Effectiveness of Next-Generation-Sequencing-Based Liquid Biopsy for Colorectal Cancer in France, Spain, and Germany
Wendelin Schramm, Germany
Abstract

PS-01-010: Quantitative detection of cell free HPV DNA in plasma samples using Nanopore Sequencing
Oliver Schauer, Germany
Abstract

PS-01-011: Clonal tracking and monitoring of minimal residual disease using longitudinal whole-genome sequencing of solid tumors and liquid biopsies in rectal cancer
Francisco Sanchez-Vega, United States
Abstract

PS-01-012: PLCRC-PROVENC3: assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients
Carmen Rubio-Alarcón, The Netherlands
Abstract

PS-01-013: Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using The Plasma-SeqSensei™ NSCLC RUO Kit at diagnostic in Lyon’s hospital
Léa Payen, France
Abstract

PS-01-014: KRAS and GNAS mutations in cell-free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms – an observational pilot-study regarding the risk of progression to pancreatic cancer
Christine Nitschke, Germany
Abstract

PS-01-015: Comparative study of streptavidin-coupled ferrofluids and magnetic beads for capture of circulating tumor cells in patients with disseminated prostate cancer
Amalie Mundt Jørgensen, Denmark
Abstract

PS-01-016: Circulating BRAF V600E levels as a biomarker for disease presence and activity in Langerhans Cell Histiocytosis
Elisabeth Mellström, Sweden
Abstract

PS-01-017: Towards a minimally invasive method for diagnosing aggressive SCCs in 'butterfly disease'
Albert Mellick, Australia
Abstract

PS-01-018: Improved detection of disease progression in metastatic breast cancer by absolute molecular counting: the 100 copies/mL question
Geert Martens, Belgium
Abstract

PS-01-019: Analysis of Cell-Free DNA in the Plasma of patients with Non-Resectable, Progressive or Relapsed Pediatric Malignancies
Kendra Maass, Germany
Abstract

PS-01-020: C-ProMeta-1: Predicting treatment failure after radical prostatectomy using circulating tumour cells
Rachel Lawrence, United Kingdom
Abstract

PS-01-021: High tumor metabolic activity is associated with circulating tumor DNA detection in early-stage lung cancer patients 
Anine Larsen Ottestad, Norway
Abstract

PS-01-023: Comparison of circulating tumor cell enrichment techniques considering tumor heterogeneity
Minseok S. Kim, Republic of Korea
Abstract

PS-01-024: Blood-based detection of lung cancer using cysteine-rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker
Lucija Ackar, Germany
Abstract

PS-02-001: Analysis of circulating tumor cells displays tumor heterogeneity in advanced prostate cancer
Lina Merkens, Germany
Abstract

PS-02-002: Characterisation of novel, patient-like cfDNA reference material for molecular diagnostic liquid biopsy assays
Björn Nowack, Germany
Abstract

PS-02-003: Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients
Keren Bahar-Halpern, Israel
Abstract

PS-02-004: Monitoring treatment efficacy using personalised circulating-tumour DNA panels in patients with metastatic breast cancer
Pia Mouhanna, Sweden
Abstract

PS-02-005: TNC positive extracellular vesicles as clinical biomarkers in glioblastoma
Amanda Salviano da Silva, Germany
Abstract

PS-02-006: Liquid biopsy in colorectal cancer beyond targeted analysis of single variants
Ariane Hallermayr, Germany
Abstract

PS-02-007: Transcriptomic analysis of circulating tumor cells in metastatic breast cancer: the new frontiers of liquid biopsy for personalized medicine
Tania Rossi, Italy
Abstract

PS-02-008: Single-center prospective study to evaluate circulating tumor cells as a monitoring tool in women with early breast cancer treated with neoadjuvant chemotherapy
Sohyun Moon, Republic of Korea
Abstract

PS-02-009: Deep learning for Circulating Tumor Cell (CTC) identification with the CELLSEARCH system: towards optimal standardization
Luca Biasiolli, Italy
Abstract

PS-02-010: It's a match - circulating tumor DNA in urine and plasma reveal complementary information in prostate cancer
Tina Moser, Austria
Abstract

PS-02-011: ctDNA testing in treatment response monitoring of patients with metastatic colorectal cancer: the DOLPHIN study
Denise van Steijn, The Netherlands
Abstract

PS-02-013: Advancing Single-Cell Proteomics with ZeptoCTC: A high-sensitivity method for analysis of Circulating Tumor Cells
Mahdi Rivandi, Germany
Abstract

PS-02-014: Comparison of DNA reference material for pre-analytics: Nucleosomal plasma-spike-ins reveal true recovery efficiencies of circulating cell-free DNA extractions
Tu Truong, Germany
Abstract

PS-02-015: Spotting the difference: rare cell characterization by multiplex mRNA in situ hybridization and machine learning in the context of liquid biopsy-based therapy resistance monitoring
Lilli Bonstingl, Austria
Abstract

PS-02-016: Liquid biopsy from Bile - a potential novel biomarker in biliary stenosis
Eva Dazert-Klebsattel, Germany
Abstract

PS-02-017: Comparative analysis of EpCAM High-Expressing and Low-Expressing Circulating Tumor Cells with regard to their clonal relationship and clinical value
André Franken, Germany
Abstract

PS-02-018: The DKTK EXLIQUID consortium – Exploiting liquid biopsies for molecular tumor board patients
Christof Winter, Germany
Abstract

PS-02-019: “Inner Allergy” – increased basal serum tryptase levels due to Hereditary Alpha-Tryptasemia and / or KIT D816V mutation may explain mast cell related symptoms
Eva Dazert-Klebsattel, Germany
Abstract

PS-02-020: Detecting and monitoring circulating tumour DNA in dried blood spots from metastatic cancer patients and xenograft mouse models
Angela An, United Kingdom
Abstract

PS-02-021: SNP detection by hyperplex digital PCR for patient sample identification
Martin Becker, France
Abstract

PS-02-023: A web-based cohort monitoring dashboard for multi-center clinical studies with biospecimens within the German Cancer Consortium (DKTK)
Patrick Skowronek, Germany
Abstract

PS-02-024: Results from an international inter-lab study of CTC enrichment and enumeration on the Genesis Rare Cell Isolation System
Adam Corner, United States
Abstract

PS-03-001: Functional analysis of live circulating tumor cells from triple negative breast cancer patients using TetherChip technology
Vasileios Vardas, Greece
Abstract

PS-03-002: Retinoic acid-induced 2 driven polymerization of C-terminal binding proteins as novel mechanism of transcriptional regulation in castration-resistant prostate cancer
Stefan Werner, Germany
Abstract

PS-03-003: Binding of circulating melanoma cell-derived extracellular vesicles to ultra-large von Willebrand factor induces cancer-associated thrombosis
Yuanyuan Wang, Germany
Abstract

PS-03-004: p53-binding protein 1 accumulation in circulating tumor cells identifies chemotherapy-responsive metastatic breast cancer patients
Kathrin Niedermayer, Germany
Abstract

PS-03-005: RAI2 controls polycomb-mediated repression of CDKN1A by its interaction with CtBP1
Sarah Greimeier, Germany
Abstract

PS-03-006: Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
Leonie Ott, Germany
Abstract

PS-03-008: Circulating tumour cell clusters in the metastatic development of prostate cancer
Edwina Burke, United Kingdom
Abstract

PS-03-009: Evaluation of the anti-tumor effects of artesunate on Circulating Tumor Cells (CTCs)
Galatea Kallergi, Greece
Abstract

PS-03-010: Evaluation of cell-free miR2110 in hepatocellular carcinoma patients’ liquid biopsies
Pelin Balcik Ercin, Turkey
Abstract

PS-03-011: In vitro biological effects of breast cancer circulating cell free DNA on normal breast cells
Ekaterini Alexiou Chatzaki, Greece
Abstract

PS-03-012: Targeted treatments in gastric adenocarcinoma circulating tumour cells: Is combination therapy the answer?
Ann-Katrin Piper, Australia
Abstract

PS-03-013: RAI2 as novel suppressor of cancer cell dissemination to the bone marrow
Thais Pereira-Veiga, Germany
Abstract

PS-03-014: Targeting BCAT1 is a metabolic vulnerability that impairs cell proliferation and aggressiveness in renal cell carcinoma
Pouria Jandaghi, Canada
Abstract

PS-03-015: Circulating tumor cells in breast cancer patients with Leptomeningeal Metastases: Detection and in vitro expansion
Laure Cayrefourcq, France
Abstract

PS-03-016: Epigenomic analysis reveals a specific DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer
Angel Diaz-Lagares, Spain
Abstract

PS-03-017: Ultra-sensitive Minimal Residual Disease (MRD) monitoring for cancer patients using SuperRCA mutation assays with Flow Cytometer Readout
Lei Chen, Sweden
Abstract

PS-03-018: The feasible approach to monitor the MRD for recurrence after the radical treatment for stage III colorectal cancer cases
Koshi Mimori, Japan
Abstract

PS-03-019: Evaluation of treatment response in paediatric leukaemia using patient specific circulating tumour DNA analysis
Fani Pujol Calderón, Sweden
Abstract

PS-03-020: Ultrasensitive amplicon based detection of circulating tumour DNA for identification of minimal residual disease
Stefan Filges, Sweden
Abstract

PS-03-021: Development of a target-capture NGS assay for use in molecular-based research of myeloid Measurable Residual Disease
Rebecca Biloune, United Kingdom
Abstract

PS-03-022: Noninvasive, dynamic risk profiling of aggressive B-cell lymphomas by peripheral blood circulating tumor DNA sequencing
Sven Borchmann, Germany
Abstract

PS-03-023: Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients
Karin Birkenkamp-Demtröder, Denmark
Abstract

PS-03-024: ctDNA BRCA1-methylation can predict therapy efficacy in ovarian and breast cancer patients
Simon Joosse, Germany
Abstract

PS-04-001: Immune checkpoints and epithelial to mesenchymal transition related molecules in triple negative breast cancer patients’ circulating tumor cells and their clinical impact
Vasileios Vardas, Greece
Abstract

PS-04-002: Expression of CXCR4, JUNB and PD-L1 in circulating tumor cells isolated from patients with prostate cancer
Argyro Roumeliotou, Greece
Abstract

PS-04-003: Detection of circulating tumor cells (CTCs) in patients with metastatic uveal melanoma - a pilot study
Shari Schneider, Germany
Abstract

PS-04-004: Circulating microRNAs as predictors of response to therapy in melanoma
Luigi Fattore, Italy
Abstract

PS-04-005: The winning liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer
Zahra Eslami Samarin, France
Abstract

PS-04-006: Assessment of CTLA4 and TIGIT expression on CTCs and PBMCs of patients with small cell lung cancer (SCLC)
Maria A. Papadaki, Greece
Abstract

PS-04-007: Cost-effectiveness analysis of cell-free DNA-based molecular tumor profiling platforms for the detection of EGFR mutations in lung cancer
Pim Rozendal, The Netherlands
Abstract

PS-04-008: Early detection of prostate cancer by investigating the host peripheral immune response
Junjie Chai, United Kingdom
Abstract

PS-04-009: CTC identification enhanced specificity by using a double exclusion biomarker assay
Adriana Carneiro, Portugal
Abstract

PS-04-011: Porous bioaffinity membranes for the isolation of circulating tumor cells
Thomas Brandstetter, Germany
Abstract

PS-04-012: Mixed MiRNA and Serum-marker Classifier for Prediction of Immunotherapy Response in Liquid Biopsies of Melanoma Patients
Marc Bender, Germany
Abstract

PS-04-013: Circulating miRNA compositions in liquid biopsies of melanoma patients as biomarker candidates for progression, PD-L1 status and overall survival
Sarah Degenhardt, Germany
Abstract

PS-04-014: ctDNA monitoring of metastatic melanoma patients receiving immunotherapy
Isabel Heidrich, Germany
Abstract

PS-04-015: D-Dimers as a liquid prognostic biomarker in melanoma patients treated with immune-checkpoint inhibitors
Tim Zell, Germany
Abstract

PS-04-016: Exosomal NGFR witnesses the dynamics of inflammation-induced dedifferentiation in TNF-α-treated melanoma cells
Benjamin Deitert, Germany
Abstract

PS-04-017: Circulatory plasma proteomic biomarkers predict response to immunotherapy in melanoma patients and reveal biological insights into the tumor microenvironment
Marijana Rucevic, France
Abstract

PS-04-018: Diagnosis of precancerous high-grade cervical lesions and cervical cancer with a panel of circulating cell-free microRNAs in a liquid biopsy approach
Annika Tamenang, Germany
Abstract

PS-04-019: Von Willebrand factor predicts response to immunotherapy in patients with metastatic melanoma
Julian Kött, Germany
Abstract

PS-04-020: Extracellular vesicle trafficking in GBM
Amanda Salviano da Silva, Germany
Abstract

PS-04-021: Th1/Tc1 polarized tissue resident memory T cells mediate checkpoint blockade–induced dermatitis and colitis via IFNγ and TNFα
Robin Reschke, United States
Abstract

PS-04-022: Analyzing tumor microenvironment difference between TNBC subtypes by meta-analysis of 7 breast cancer scRNAseq studies
Kyungsoo Kim, Republic of Korea
Abstract

PS-05-001: The role of circulating tumor cells in the course of disease and therapy of high-grade-serous ovarian cancer patients
Annabelle Lobermeyer, Germany
Abstract

PS-05-002: Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma
Benjamin Stubbe, Denmark
Abstract

PS-05-003: Multi-platform analysis of the heterogeneity of circulating melanoma cells and tumor DNA as useful tool to track disease evolution and targeted therapy response
Maria Chiara Scaini, Italy
Abstract

PS-05-004: Targeted mutation detection in individual circulating tumor cells using a modified UltraSEEK® workflow for the MassARRAY® System
Laura Keller, Germany
Abstract

PS-05-005: Ultrasensitive molecular residue disease detection enabled by genome wide concatmer error correction
Paul Tang, United States
Abstract

PS-05-006: Investigating potential circulating tumor cell release following breast cancer biopsy
Nikhil Kalra, Germany
Abstract

PS-05-007: New droplet digital PCR for highly sensitive detection of microsatellite instability
Valerie Taly, France
Abstract

PS-05-008:Liquid biopsy beyond cancer – circulating epigenetic biomarkers in cardiovascular and immune-mediated diseases
Lucia Ciglar, Austria
Abstract

PS-05-009: A novel, automated approach providing standardized sample preparation for multiple Liquid Biopsy analyses
Roberta Carbone, Italy
Abstract

PS-05-010: Evaluation of new therapeutic targets in circulating tumor cells and exosomes isolated from small cell lung cancer patients
Dimitrios Papakonstantinou, Greece
Abstract

PS-05-011: Association of CTC and MTV in pancreatic cancer
Hyun Soo Shin, Republic of Korea
Abstract

PS-05-012: Possible role of circulating tumour cells (CTCs) for outcome prediction of salvage lymph node dissection in patients with early prostate cancer recurrence
Tobias Maurer, Germany
Abstract

PS-05-013: Microfluidic detection of circulating tumor cells from pediatric sarcoma patients
Minh-Chau Le, United States
Abstract

PS-05-014: Personalised analysis of circulating tumor DNA as a novel biomarker in neuroblastoma
Ida Rahmqvist, Sweden
Abstract

PS-05-015: Marker-independent enrichment of circulating tumor cells from leukapheresis by non-tumor cell depletion
Lena Willnow, Germany
Abstract

PS-05-016: Detection of circulating tumor cells from a multi-cancer cohort using the recombinant malaria protein rVAR2
Caroline Løppke, Denmark
Abstract

PS-05-018: The role of circulating tumor cells in vulvar carcinoma
Leonie Elisabeth Kleinholz, Germany
Abstract

PS-06-001: Circadian rhythm and circulating cell-free DNA release on healthy subjects
Valerie Taly, France
Abstract

PS-06-002: Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
Florian Janke, Germany
Abstract

PS-06-003: Monitoring response to targeted treatment in children with ALK-driven neuroblastoma using a novel assay for detection of circulating tumor DNA
Raghda Ibrahim, Sweden
Abstract

PS-06-004: Self-supervised learning for detection and classification of circulating tumor cells in liquid biopsy data
Hümeyra Husseini, Germany
Abstract

PS-06-005: Use of a highly sensitive and specific minimal residual disease test to characterize novel cell-free DNA reference material
Annett Helfrich-Kröger, Germany
Abstract

PS-06-006: Detection of multiple HPV types in liquid biopsies of cervical neoplasia
Johanna Herbst, Germany and Vanessa Vohl, Germany
Abstract

PS-06-007: Impact of reference materials for analytical performance evaluation of liquid biopsy NGS assays
Ariane Hallermayr, Germany
Abstract

PS-06-008:Feasibility and efficacy of adjuvant chemotherapy in stage II colon cancer patients with detectable circulating tumor DNA after surgery
Ingrid Franken, The Netherlands
Abstract

PS-06-009: ExTarget– Circulating tumor DNA profiling for response assessment and MRD monitoring in molecular tumor board patients
Stephanie Fliedner, Germany
Abstract

PS-06-010: Monitoring the release of tumor cells before, during and after prostatectomy
Gresa Emurlai, Germany
Abstract

PS-06-011: Performance of ddPCR and qPCR to detect cell-free HPV16 DNA in liquid biopsies from patients with HPV-related oropharyngeal squamous cell carcinoma at diagnosis and recurrence
Imke Demers, The Netherlands
Abstract

PS-06-012: Cell-free tumor DNA analysis during immunotherapy to monitor clinical response for patients with non-small cell lung cancer
Anna Rohlin, Sweden
Abstract

PS-06-013: UCCSH NGSP: Improvement of molecular tumor board decisions with a ctDNA-based deep scale cross-entity NGS panel
Eva Dazert-Klebsattel, Germany
Abstract

PS-06-014: Evaluation of a multi-omics approach to molecular residual disease detection
Archana Ramesh, United States
Abstract

PS-06-015: Exploring the clinical relevance of circulating tumor cells and tumor-derived extracellular vesicles collected from different blood compartments in colorectal cancer patients
Stefan Cieslik, Germany
Abstract

PS-06-016: A targeted-enzymatic-methyl-seq approach for cell-free DNA methylation analysis to improve cancer detection, disease following and minimal residual disease monitoring
Mehdi Ben Sassi, France
Abstract

PS-06-017: Identification of atypical cells in the blood of non-small cell lung cancer (NSCLC) patients
Yassine Belloum, Germany
Abstract

PS-06-018: Integrated circulating tumor DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
Arlou Kristina Angeles, Germany
Abstract

PS-06-019: Gene methylation and levels of circulating tumor DNA as diagnostic/prognostic biomarkers in Pancreatic Cancer: biosignatures built via automated Machine Learning
Ekaterini Alexiou Chatzaki, Greece
Abstract

PS-06-020: Classification of brain tumors by Nanopore sequencing of cell-free DNA from cerebrospinal fluid
Ann-Kristin Afflerbach, Germany
Abstract

PS-06-021: OUTLIVE-CRC: Improvement of prognosis of young colorectal cancer patients through multimarker models and nutritional medical intervention – focus on liquid biopsy-based ctDNA genomics
Eva Dazert-Klebsattel, Germany
Abstract

PS-06-022: Extracellular vesicle (EV) associated DNA: potential liquid biopsy biomarker and functional communicators in cancer
Basant Kumar Thakur, Germany
Abstract